Literature DB >> 26666888

[Memantine for optic nerve atrophy in Friedreich's Ataxia].

S Peter1, K Manousaridis2, S Boesch3, S Mennel2.   

Abstract

A 24-year-old patient with Friedreich's ataxia presented with advanced visual loss due to optic nerve atrophy. After interdisciplinary consultation and after obtaining informed consent, an off-label therapy with the N-methyl-D-aspartate (NMDA) antagonist memantine was initiated. In a 1-year follow-up no further loss of the nerve fiber layer could be detected by optical coherence tomography (OCT) and visual acuity remained stable. Despite the limitations of this single and time limited case observational study, memantine should be discussed as an option for treatment of acute optic nerve atrophy in Friedreich's ataxia.

Entities:  

Keywords:  Citicoline; Neuroprotection; Off label use; Visual acuity; Visual impairment

Mesh:

Substances:

Year:  2016        PMID: 26666888     DOI: 10.1007/s00347-015-0191-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  10 in total

Review 1.  Co-enzyme Q10 and idebenone use in Friedreich's ataxia.

Authors:  Michael H Parkinson; Jörg B Schulz; Paola Giunti
Journal:  J Neurochem       Date:  2013-08       Impact factor: 5.372

Review 2.  Mitochondrial optic neuropathies - disease mechanisms and therapeutic strategies.

Authors:  Patrick Yu-Wai-Man; Philip G Griffiths; Patrick F Chinnery
Journal:  Prog Retin Eye Res       Date:  2010-11-26       Impact factor: 21.198

Review 3.  Deferiprone for the treatment of Friedreich's ataxia.

Authors:  Massimo Pandolfo; Laura Hausmann
Journal:  J Neurochem       Date:  2013-08       Impact factor: 5.372

Review 4.  Erythropoietin in Friedreich ataxia.

Authors:  Caterina Mariotti; Wolfgang Nachbauer; Marta Panzeri; Werner Poewe; Franco Taroni; Sylvia Boesch
Journal:  J Neurochem       Date:  2013-08       Impact factor: 5.372

5.  Scale for the assessment and rating of ataxia: development of a new clinical scale.

Authors:  T Schmitz-Hübsch; S Tezenas du Montcel; L Baliko; J Berciano; S Boesch; C Depondt; P Giunti; C Globas; J Infante; J-S Kang; B Kremer; C Mariotti; B Melegh; M Pandolfo; M Rakowicz; P Ribai; R Rola; L Schöls; S Szymanski; B P van de Warrenburg; A Dürr; T Klockgether; Roberto Fancellu
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

6.  Ophthalmic features of Friedreich ataxia.

Authors:  S Noval; I Contreras; I Sanz-Gallego; R K Manrique; J Arpa
Journal:  Eye (Lond)       Date:  2011-11-18       Impact factor: 3.775

7.  Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial.

Authors:  Silvia Romano; Giulia Coarelli; Christian Marcotulli; Luca Leonardi; Francesca Piccolo; Maria Spadaro; Marina Frontali; Michela Ferraldeschi; Maria Chiara Vulpiani; Federica Ponzelli; Marco Salvetti; Francesco Orzi; Antonio Petrucci; Nicola Vanacore; Carlo Casali; Giovanni Ristori
Journal:  Lancet Neurol       Date:  2015-08-25       Impact factor: 44.182

8.  Visual system involvement in patients with Friedreich's ataxia.

Authors:  Filippo Fortuna; Piero Barboni; Rocco Liguori; Maria Lucia Valentino; Giacomo Savini; Cinzia Gellera; Caterina Mariotti; Giovanni Rizzo; Caterina Tonon; David Manners; Raffaele Lodi; Alfredo A Sadun; Valerio Carelli
Journal:  Brain       Date:  2008-10-18       Impact factor: 13.501

9.  Amantadine hydrochloride treatment in heredodegenerative ataxias: a double blind study.

Authors:  M I Botez; T Botez-Marquard; R Elie; O L Pedraza; K Goyette; R Lalonde
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-09       Impact factor: 10.154

Review 10.  Neuroprotective properties of citicoline: facts, doubts and unresolved issues.

Authors:  Pawel Grieb
Journal:  CNS Drugs       Date:  2014-03       Impact factor: 5.749

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.